







an Open Access Journal by MDPI

# **Leading Diagnosis and Management of Multiple Sclerosis**

Guest Editors:

### Dr. Dániel Sandi

Department of Neurology, University of Szeged, 6725 Szeged, Hungary

### Dr. Krisztina Bencsik

Department of Neurology, University of Szeged, 6725 Szeged, Hungary

Deadline for manuscript submissions:

closed (31 May 2024)

# **Message from the Guest Editors**

In the past 15 years, we have entered a new era of multiple sclerosis treatment. Nowadays, more than 15 disease-modifying therapies are utilized for all clinical courses, making the management of even the most aggressive cases possible.

However, with new knowledge, new questions always arise. We still lack any validated reliable biomarker for either the activity, the progression or the prognosis of the disease. We still cannot predict the effect of disease-modifying treatments at initiation, and many DMTs still lack long-term real-world data on effectivity. Additionally, the less commonly measured, yet highly debilitating symptoms of the disease—cognitive impairment, fatigue and mood disorders—are still underdiagnosed and undertreated despite their grave effect on patients' quality of life and overall progression.

Therefore, we wholeheartedly invite global practitioners and investigators to submit original research articles or review articles to this Special Issue.













an Open Access Journal by MDPI

### **Editor-in-Chief**

### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

## **Message from the Editor-in-Chief**

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

#### **Contact Us**